NeuroScientific Biopharmaceuticals (ASX:NSB) has acquired the patented StemSmartTMstem cell technology from Isopogen WA to deliver potent and clinically promising cellular medicine for immune-related diseases.



🔬Exclusive rights secured to patented StemSmartTM stem cell technology for treating inflammatory and immune-related diseases

🔬StemSmartTM interacts with immune system to modulate immune responses

🔬Strong early trial results in patients with Crohn’s disease and other serious conditions, with multiple positive clinical responses



“We’re incredibly excited to add mesenchymal stem cell technology to our growing portfolio. This acquisition not only complements our existing pipeline of therapeutic peptides, but also strategically positions us at the forefront of next-generation biologics.” – Dr Anton Uvarov, Founding Director of NeuroScientific

AML3D Limited (ASX:AL3) has announced the largest custom ARCEMY® system ever built. The system was installed at the US Navy’s AM Center of Excellence in Danville VA, that has been setup and operated by Austal USA. Bringing the system online triggers payment of the final 50% of the contract value.

🇺🇲 The custom ARCEMY® system supports Austal USA’s drive to further embed additive manufacturing into the U.S. Navy’s supply chain.
🇺🇲 Austal USA leads and operates the Navy’s Additive Manufacturing Center of Excellence in Danville, Virginia, which currently operates a large scale ARCEMY® 6700 system delivered in early 2024.
🇺🇲 A second custom ARCEMY® system was recently installed, featuring a massive 11,000kg positioner and over four meters of linear rail, enabling a build volume of approximately 35 cubic meters—making it the largest of its kind

“The successful delivery the custom ARCEMY® system to Austal USA (refer to ASX announcement November 20,2023) aligns with our ambitions to expand the range of U.S.
defense work we do. AML3D already has a track record of deploying our WAM Additive Manufacturing technology in support of the U.S. Navy submarine industrial base. Those successes are translating to an adoption of additive manufacturing technology in the wider U.S. Marine Industrial Base, covering shipbuilding and munitions". - Sean Ebert, AML3D CEO

Neuren Pharmaceuticals (ASX:NEU) has secured FDA confirmation of primary endpoints for its Phase 3 clinical trial of a new drug therapy to treat Phelan-McDermid Syndrome (PMS).

🧬 Between 8,000-15,000 have PMS, and there are no medication, drugs or therapies to treat it, causing an overwhelming unmet medical need

🧬 PMS affects a region of chromosome 22 that supports synapses in the brain, severely impacting quality of life

🧬 Neuren’s trial which commences in mid-2025 marks the first ever Phase 3 trial for PMS in children

“We are very pleased with the outcome of another constructive discussion with the FDA and are now excited to be able to move forward as planned with the first ever Phase 3 trial in children with Phelan-McDermid syndrome.” – Jon Pilcher, CEO of Neuren

Australian game developer Streamplay Studio (ASX:SP8) has reported strong first-quarter performance, with its subsidiary Noodlecake generating $2.7M in revenue and preparing to launch several high-profile games.

 Subsidiary Noodlecake generated $2.7M revenue in Q1 following acquisition by Streamplay on 1 January 2025
 Upcoming mobile title Super Flappy Golf has achieved over 50,000 pre-orders
 Over 30 new game pitches and strategic partnerships explored at Game Developers Conference (GDC) 2025

“We’ve been very pleased with how seamlessly the Noodlecake team has integrated, and we’re now strongly focused on driving growth both organically and through the
identification of complementary assets to bring into the group.” — Bert Mondello, Chairman of Streamplay Studio

Kincora Copper Limited (TSXV:KCC, ASX:KCC) has secured its second major earn-in with AngloGold Ashanti (JSE:ANG; NYSE:AU).The deal opens the way for more extensive exploration in the Northern Junee-Narromine Belt of the Macquarie Arc, Central West NSW, Australia.

⛏️ Multiple-year deal for the Nyngan South, Nevertire South and Mulla projects
⛏️ AngloGold Ashanti may earn a 70% interest by spending $25 million
⛏️Kincora remains the operator, receiving a 10% management fee

“We are very pleased to broaden our partnership with AngloGold Ashanti. It comes as we continue to progress our ongoing exploration program at the Nyngan project, with a ground gravity survey and hole twelve of the scout drilling program recently completed." - Kincora Copper Technical Committee chair, John Holliday and VP of Exploration Peter Leaman

The USA’s status as a global super-power is under the microscope and Teaminvest Private Group (ASX:TIP) CEO Andrew Coleman identifies where to invest as USA’s economic power wanes:

📉 Recession reality: TIP believes the US recession is no longer looming; it`s arrived and says "Liberation Day" may go down as the moment things truly unraveled.

🛠️ People and productivity: Since the 16th century, growth has come from more workers or more output per worker and TIP says shrinking the workforce and blocking innovation breaks that math.

🌪️ Defying economic gravity: TIP warns policies that ignore fundamentals might seem bold, but gravity doesn’t care if you believe in it, it happens.

What is the VIX, and why does it spike during a crash?

#finance #fintok #stocks #shares #investing #wallstreet #VIX #fear #trump #trumptariffs

Elsight Limited (ASX:ELS) has secured a US$4.28 million supply deal with its European-based defence OEM (original equipment manufacturer) customer for its AI-powered Halo connectivity platform.

📡 European defence drone OEM customer commits to US$4.28 million in additional purchases over next four months (April-July 2025)
📡 Deal follows the initial production order of US$300,000 last month and signifies an escalation in scale and scope of the engagement
📡 Initial production order allowed customer to conclude an extensive and successful field integration

“This commitment is a major validation of the value, reliability and strategic position of our solution. After a long and extensive period of field testing, the Customer’s fast move to production based on field deployment success, and already progressed to a multi-million-dollar scale-up phase within a few months, highlights just how critical reliable communications are in modern defence operations.” – Yoav Amitai, CEO of Elsight